BPG is committed to discovery and dissemination of knowledge
Articles in Press
1/20/2023 11:48:41 PM | Browse: 77 | Download: 105
Publication Name World Journal of Gastroenterology
Manuscript ID 80502
Country/Territory India
Category Gastroenterology & Hepatology
Manuscript Type Minireviews
Article Title Immunotherapy for hepatocellular carcinoma: Current status and future perspectives
Manuscript Source Invited Manuscript
All Author List Deepa S Mandlik, Satish K Mandlik and Heena B Choudhary
Funding Agency and Grant Number
Corresponding Author Deepa S Mandlik, PhD, Assistant Professor, Department of Pharmacology, BVDU, Poona College of Pharmacy, Kothrud, Pune 411038, Maharashtra, India. deepa.mandlik@bharatividyapeeth.edu
Key Words Hepatocellular carcinoma; Immunotherapy; Immune checkpoint inhibitors; Alpha-fetoprotein; Cancer vaccine; Combination therapies
Core Tip Core Tip: Hepatocellular carcinoma (HCC) is a multifaceted illness with multiple faces. It avoids early discovery, which provides the best chance of cure by resection/transplant, and systemic treatments are only of marginal efficacy at best, despite recent therapeutic advances. Current advances in immunotherapy and its combinations have altered the HCC treatment landscape, and clinical studies are continuing to pave the path forward. Immunotherapy increases survival rates and provides long-term cancer control in subsets of HCC patients while also minimising side effects. Further research into immunotherapy in combination with current treatments for HCC in the early and intermediate stages may assist a greater spectrum of patients. Continued research into programmed cell death 1/ programmed cell death ligand 1, TMB, ctDNA, microsatellite stability, DNA mismatch repair, neutrophil/lymphocyte ratio, cytokines, and cellular peripheral immune response will hopefully identify the most reliable marker for selecting and sequencing systemic treatments to achieve the best outcome in HCC patients. Despite such significant treatment advances in HCC, numerous hurdles remain. The scientific community must figure out how to appropriately sequence these medicines for the best potential response, how to control toxicities, and how to develop indicators to monitor for response and relapse.
Citation Mandlik DS, Mandlik SK, Choudhary HB. Immunotherapy for hepatocellular carcinoma: Current status and future perspectives. World J Gastroenterol 2023; 29(6): 1054-1075
2022-09-29 16:19
Peer-Review Started
2022-09-29 16:20
To Make the First Decision
Return for Revision
2022-12-12 08:16
2022-12-23 06:26
Second Decision
2023-01-20 03:30
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2023-01-20 23:48
Articles in Press
2023-01-20 23:48
Publication Fee Transferred
Edit the Manuscript by Language Editor
2023-01-27 17:59
Typeset the Manuscript
2023-01-30 07:07
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Assistant Editor Assistant Editor
Science Editor Yu-Lu Chen
Reviewer Code 06272301, and 06457333
Editorial Director
Journal Chief Editor
Company Chief Editor Li Ma
Language Editor Donna Fox
Production Editor Hua-Ge Yu
Responsible Production Editor Hua-Ge Yu
Responsible Science Editor
Proofing Editorial Director Jin-Lei Wang
Proofing Editor-in-Chief Lian-Sheng Ma